Pharmaceuticals

SHERIDAN, WYOMING - May 13, 2026 - TuHURA Biosciences, Inc. (NASDAQ: HURA), a Phase 3 immuno-oncology company focused on overcoming resistance to cancer immunotherapy, has confirmed that President and Chief Executive Officer James A. Bianco, M.D., will participate in a fireside chat at the 4th Annual H.C. Wainwright BioConnect Investor Conference in New York City on May 19, 2026, at 2:00 pm ET. The appearance gives institutional investors and sector analysts direct access to leadership at a moment when TuHURA is running an active Phase 3 registration trial and advancing two additional pipeline programs. For stakeholders tracking immuno-oncology development timelines and clinical positioning, the session represents a structured opportunity to assess the company's near-term milestones.

SHERIDAN, WYOMING - May 10, 2026 - Fette Compacting has formally introduced its comprehensive R&D Solutions program, transitioning the company from a traditional equipment supplier to an integrated process partner for pharmaceutical manufacturers. The newly structured service framework supports drug developers from initial powder formulation through to validated commercial serial production. By embedding Quality by Design principles early in the development lifecycle, the initiative directly addresses the critical need to accelerate time-to-market and maximize effective patent exclusivity periods. This strategic realignment aims to eliminate isolated development steps, ensuring that complex critical material attributes are seamlessly aligned with final production parameters.

SHERIDAN, WYOMING - March 21, 2026 - HubSpot has published a new guide comparing Claude and ChatGPT for marketers, focusing on three practical buying criteria: pricing, integrations, and use cases. The article frames AI model selection as an operational decision rather than a purely technical one, aimed at helping marketing teams choose the right large language model for day-to-day work. For business users, that matters because LLM choice can affect tool compatibility, workflow design, and budget planning across content and campaign functions.

SHERIDAN, WYOMING - March 13, 2026 - Roche has reported positive Phase II results for petrelintide, an amylin analog being developed for people living with overweight and obesity. According to the company, petrelintide delivered up to 10.7% mean body weight reduction at week 42 compared with 1.7% for placebo, with a p-value of less than 0.001. Roche also said the maximally effective dose showed placebo-like tolerability, with no vomiting cases and no treatment discontinuations due to gastrointestinal adverse events. For the obesity treatment market, the update is relevant because efficacy and tolerability remain central to prescribing, adherence and competitive positioning.

SHERIDAN, WYOMING - December 19, 2025 - Eli Lilly's experimental daily oral obesity medicine orforglipron posted Phase III data suggesting it can help patients maintain weight loss after long-term treatment with injectable GLP-1 therapies-an outcome with direct implications for adherence, payer strategy, and competition with Novo Nordisk's coming oral semaglutide filing.

SHERIDAN, WYOMING - December 19, 2025 - Merck reported positive topline Phase 3 data showing its immunotherapy KEYTRUDA (pembrolizumab) combined with the antibody-drug conjugate Padcev (enfortumab vedotin-ejfv) improved event-free survival, overall survival and pathologic complete response when used before and after surgery in cisplatin-eligible muscle-invasive bladder cancer (MIBC), setting up a potential shift in the perioperative standard of care.

SHERIDAN, WYOMING - December 19, 2025 - Merck said the EMA's CHMP has recommended approval of an expanded European indication for WINREVAIR (sotatercept) in adults with pulmonary arterial hypertension (PAH), a move that-if confirmed by the European Commission-could broaden use to include WHO Functional Class (FC) IV patients and strengthen the product's positioning around morbidity and mortality benefit.

SHERIDAN, WYOMING - December 19, 2025 - The FDA is considering awarding Commissioner's National Priority Vouchers to two investigational Merck programs-PCSK9 pill enlicitide decanoate and antibody-drug conjugate sacituzumab tirumotecan-an early signal that the agency may be willing to accelerate reviews for high-impact products even before formal filings, according to a Reuters report.

A new FDA lever that can reshape launch timing
Commissioner's National Priority Vouchers are designed to shorten the FDA's regulatory review window from the typical 10-12 months to 1-2 months. For large pharma, that time compression can meaningfully shift competitive dynamics-pulling forward commercialization, altering payer and guideline sequencing, and increasing the urgency of manufacturing readiness, launch supply, and field execution.

SHERIDAN, WYOMING - December 15, 2025 - TuHURA Biosciences (NASDAQ: HURA) has provided a corporate update following a recent $15.6 million equity financing, detailing near-term milestones across its Phase 3 IFx-2.0 program in Merkel cell carcinoma, its VISTA-inhibiting antibody TBS-2025 in AML, and its Delta Opioid Receptor (DOR)-focused conjugate platform aimed at overcoming resistance to cancer immunotherapy.

SHERIDAN, WYOMING - December 15, 2025 - TuHURA Biosciences, Inc. (NASDAQ:HURA) announced that Kintara's REM-001 clinical trial in ten metastatic cutaneous breast cancer patients met its primary endpoint demonstrating safety, a contractual milestone that is expected to trigger distribution of TuHURA common stock to eligible contingent value right (CVR) holders.